Valeant Pharmaceuticals International, Inc. (VRX)

Check out top investors' recommendation for VRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. It offers dermatology products, such as Zovirax Ointment, Xerese, Retin-A Micro, Elidel, Carac, Acanya gel, Sculptra and Sculptra Aesthetic, Atralin, Solodyn, Zyclara, Ziana, Vanos, Restylane family of products, and Dysport; over-the-counter (OTC) products, including CeraVe and AcneFree; dentistry products, such as Arestin and Teeth Whitening System; ophthalmology products, including Timoptic, Timoptic, Macugen, and Visudyne; and neurology and other products, such as Wellbutrin XL and Xenazine in the United States. The company also provides pharmaceutical products, including Tiazac XC, Wellbutrin XL, Zovirax, Benzaclin, and Penlac; and Cold-FX, an OTC product in Canada, as well as Duromine/Metermine, Difflam, Duro-Tuss, and Rikodeine in Australia. In addition, it offers a range of treatments, including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products, and diabetic therapies, as well as a range of various OTC products in Europe; and products for a range of therapeutic classes, including vitamin deficiency, antibacterials, and dermatology in Mexico and Brazil. Further, the company provides Duromine, Andolex, and Pholtex products in South Africa; and Difflam, Duro-Tuss, Tambocor, and Norgesic in Asia. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Louise Chen Guggenheim Securities LLC Buy   Aug 16, '17     23.00  Aug 16, '18  N/A 
David Steinberg Deutsche Bank Securities Buy   Aug 11, '17     18.00  Aug 11, '18  N/A 
David Amsellem Piper Jaffray Sell   Jul 12, '17     10.00  Jul 12, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Jun 29, '17     35.00  Jun 29, '18  N/A 
Louise Chen Guggenheim Securities LLC Buy   Jun 28, '17     23.00  Jun 28, '18  N/A 
Venu Vasudevan Unaffiliated Buy   Feb 22, '17   16.35  19.00  Mar 22, '17  -34.43% 
David Risinger Morgan Stanley Buy   Nov 02, '16     42.00  Nov 02, '17  N/A 
David Risinger Morgan Stanley Buy   Aug 17, '16     42.00  Aug 17, '17  N/A 
Lennox Gibbs TD Newcrest Buy   Aug 13, '16     38.00  Aug 13, '17  N/A 
Corey Davis Jefferies & Co. Buy   Aug 10, '16     40.00  Aug 10, '17  N/A 
David Amsellem Piper Jaffray Sell   Aug 10, '16     22.00  Aug 10, '17  N/A 
Gerardo Torculas Unaffiliated Buy   May 29, '16   28.45  32.00  Jun 29, '16  -29.70% 
David Amsellem Piper Jaffray Sell   Mar 15, '16   33.51    Mar 15, '17  67.50% 
Louise Chen Guggenheim Securities LLC Buy   Mar 11, '16   69.55  145.00  Mar 11, '17  -82.40% 
David Steinberg Deutsche Bank Securities Buy   Mar 01, '16   65.45  106.00  Mar 01, '17  -78.03% 
Neil Maruoka Canaccord Genuity Buy   Feb 25, '16   84.71  170.00  Feb 25, '17  -80.90% 
Douglas Miehm RBC Capital Markets Buy   Feb 23, '16   79.27    Feb 23, '17  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Feb 23, '16   79.27  200.00  Feb 23, '17  -79.37% 
Chris Schott JPMorgan Buy   Feb 22, '16   75.92  200.00  Feb 22, '17  -78.40% 
Ram Selvaraju Aegis Capital Buy   Feb 16, '16   91.26  150.00  Feb 16, '17  -81.53% 
< previous1234567